Orient Bio

Orient Bio EBITDA per Share

The EBITDA per Share of Orient Bio (002630.KS) as of Oct 24, 2026 is -34.85 KRW. In the previous year, EBITDA per Share was -14.48 KRW — a change of 140.65% (lower).

EBITDA per Share

-34.85KRW

YoY

140.65%

Last updated:

EBITDA per Share of Orient Bio is 2026 -34.85 KRW. EBITDA per Share of Orient Bio was 2025 -14.48 KRW. It decreases by 140.65% lower compared to the previous year.

The Orient Bio EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
-83.38 KRW
Jan 1, 2020
-82.89 KRW
Jan 1, 2021
37.70 KRW
Jan 1, 2022
-13.27 KRW
Jan 1, 2023
42.77 KRW
Jan 1, 2024
53.04 KRW
Jan 1, 2025
-14.48 KRW
Jan 1, 2026
-34.85 KRW
The Orient Bio EBITDA per Share history
YEAREBITDA per ShareYoY
-34.85KRW+140.65%
-14.48KRW-127.30%
53.04KRW+24.01%
42.77KRW-422.38%
-13.27KRW-135.19%
37.70KRW-145.48%
-82.89KRW-0.58%
-83.38KRW+49.33%
-55.84KRW-49.12%
-109.74KRW-349.89%
43.91KRW+218.25%
13.80KRW-173.46%
-18.78KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orient Bio Stock analysis

What does Orient Bio do? Orient Bio Inc generates revenue through the production and supply of laboratory animals such as mice, rats, guinea pigs, hamsters, SPF rabbits, and beagles. The company also offers CRO services including safety assessments and new drug development, alongside medical and library equipment like barrier systems. Additional income comes from support services such as rodent surgery, laboratory diagnostics, transgenic services, and genetic testing. The firm further provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines through its subsidiaries. Orient Bio Inc's primary customers include research institutions, pharmaceutical companies, and medical facilities requiring laboratory animals and specialized services. The company's product segments consist of live animals, CRO services, medical equipment, and ancillary products like feeds and reagents. Subsidiaries contribute to revenue by supplying complementary items such as disinfectants and power supply equipment. The business model leverages a diversified portfolio of biotechnology products and services, targeting both direct research and development needs and ancillary support requirements. Revenue streams are derived from the sale of animals, provision of CRO services, equipment sales, and subsidiary product lines, ensuring steady income across multiple segments. Orient Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orient Bio stock

EBITDA per Share of Orient Bio is -34.85 KRW in 2026.

EBITDA per Share of Orient Bio changed from -14.48 KRW to -34.85 KRW, representing a 140.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Orient Bio since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Orient Bio

All Key Metrics — Orient Bio